Hata, Aaron N <br/><br/>
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.  [electronic resource] 

 -  Nature medicine  Mar 2016 
 - 262-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1546-170X 
<br/><br/><label>Standard No.: </label>10.1038/nm.4040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Drug Resistance, Neoplasm--drug effects<br/>ErbB Receptors--antagonists & inhibitors<br/>Gefitinib<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>In Vitro Techniques<br/>Lung Neoplasms--drug therapy<br/>Mutation<br/>Protein Kinase Inhibitors--pharmacology<br/>Quinazolines--pharmacology<br/>RNA, Messenger--drug effects<br/>Reverse Transcriptase Polymerase Chain Reaction